TNF and psoriasis: The hypothesis of cardiovascular risk reduction in psoriasis patients receiving ustekinumab (81) was further questioned by the observation of no substantially different risk of major adverse cardiovascular events among TNF-a inhibitors, ustekinumab or placebo therapy in several studies (82–85).